Education
About Us
Working with TipRanks
Follow Us
Precigen, Inc. (PGEN)
:PGEN
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.1Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 19, 2025
|% Change Since: 1.12%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook, with significant progress in regulatory approval, commercial readiness, and promising clinical data for multiple programs. Despite an increased net loss and pending confirmatory trials, the positive developments and strategic readiness for PRGN-2012's launch overshadowed the lowlights.Company Guidance
During Precigen's Full Year 2024 Financial Results and Business Update Call, the company provided comprehensive guidance on various metrics surrounding their lead asset, PRGN-2012 for recurrent respiratory papillomatosis (RRP). The program has shown a 51% complete response rate in clinical trials, with a median durability of response at 24 months and all Phase 1 complete responders remaining surgery-free for three years. The FDA accepted their Biologics License Application (BLA) with a priority review and a PDUFA date set for August 27, 2025, without plans for an advisory committee meeting. Precigen reported a net loss of $126.2 million for 2024, compared to $95.9 million in 2023, and ended the year with $97.9 million in cash, cash equivalents, and investments. The company plans to target approximately 500 otolaryngologists in the U.S. with a sales force of 15-20 representatives in partnership with EVERSANA, anticipating commercial revenues beginning in the second half of 2025. The potential patient population in the U.S. is estimated at 27,000 adults, indicating a significant unmet need.PRGN-2012 FDA Priority Review
PRGN-2012 received FDA priority review with a PDUFA date set for August 27, 2025, indicating a strong regulatory progress and potential market entry.
Significant Efficacy in PRGN-2012 Trials
PRGN-2012 demonstrated a 51% complete response rate, with responders remaining surgery-free for up to three years, showcasing significant efficacy and durability.
Manufacturing Readiness for PRGN-2012
The company has upgraded its GMP facility and completed process validations, ensuring readiness for the commercial launch of PRGN-2012.
Expansion of Commercial Team
Precigen completed the build-out of its commercial leadership team and partnered with EVERSANA to implement the US launch, indicating robust preparations for commercialization.
Increased Market Opportunity
Updated analysis suggests there are up to 27,000 adult RRP patients in the US, indicating a larger market opportunity than previously estimated.
Successful Fundraising
Precigen raised $79 million through a preferred stock issuance, strengthening its balance sheet and extending its financial runway into 2026.
Promising Developments in PRGN-2009 and UltraCAR-T
Phase 1 data for PRGN-2009 showed 30% objective responses in refractory patients, and UltraCAR-T platform developments indicate potential first-in-class treatments for AML and autoimmune diseases.
---
PGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 19, 2025 | $1.79 | $1.80 | +0.56% |
| Nov 14, 2024 | $0.88 | $0.82 | -6.82% |
| Aug 14, 2024 | $1.12 | $1.07 | -4.46% |
| May 14, 2024 | $1.37 | $1.44 | +5.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Precigen, Inc. (PGEN) report earnings?
Precigen, Inc. (PGEN) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Precigen, Inc. (PGEN) earnings time?
Precigen, Inc. (PGEN) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PGEN EPS forecast?
PGEN EPS forecast for the fiscal quarter 2025 (Q1) is -0.08.
---